Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Erythropoiesis-Stimulating Agent (ESA), Erythropoiesis Stimulating Agent
Erythropoiesis-Stimulating Agent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Vadadustat | EXPERIMENTAL | Study drug will be administered three times a week. |
| Erythropoiesis-Stimulating Agent (ESA) | ACTIVE_COMPARATOR | Dose adjustments will be determined by hemoglobin (Hb) change and current dose of ESA, per ESA dosing protocol |
| Name | Type | Description |
|---|---|---|
| Erythropoiesis-Stimulating Agent (ESA) | DRUG | Administered by intra-venous (IV) infusion. |
| Vadadustat | DRUG | 300mg, oral tablets |
Inclusion Criteria: * Adult participants ≥18 years of age. * Receiving outpatient in-center hemodialysis for ESKD at least three times a week. * Currently prescribed or meets criteria for ESA based on approved facility policy. * Hb \> 8 grams per deciliter (g/dl). * Serum ferritin ≥100 nanograms pe...
Erythropoiesis-Stimulating Agent (ESA) is used for the treatment of anemia of chronic kidney disease (CKD). It is being developed by Akebia Therapeutics, Inc. (AKBA) and is currently in Phase 3 clinical development. The drug is intended for patients with anemia associated with CKD, including those receiving in-center hemodialysis.
Erythropoiesis-Stimulating Agent (ESA) is a small molecule that stimulates erythropoiesis, the production of red blood cells. It is designed to treat anemia of chronic kidney disease by promoting the body's natural production of red blood cells, thereby increasing hemoglobin levels and reducing the need for blood transfusions.
Erythropoiesis-Stimulating Agent (ESA) is being developed by Akebia Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AKBA. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with anemia of chronic kidney disease.
Erythropoiesis-Stimulating Agent (ESA) is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is evaluating the drug's efficacy compared to standard of care in patients with anemia of chronic kidney disease receiving hemodialysis.
Erythropoiesis-Stimulating Agent (ESA) is being studied in a Phase 3 clinical trial with the identifier NCT06901505. This trial is evaluating the efficacy of three times weekly (TIW) vadadustat compared to standard of care ESA in patients with anemia of chronic kidney disease receiving in-center hemodialysis. The trial is active but not recruiting, with an enrollment of 353 participants in the United States.
Erythropoiesis-Stimulating Agent (ESA) is also known as Erythropoiesis-Stimulating Agent (ESA) and Erythropoiesis Stimulating Agent. In the clinical trial NCT06901505, the drug being studied is referred to as vadadustat, which is the active agent being evaluated for the treatment of anemia of chronic kidney disease.